Home

Medtronic has issued the following statement regarding revised clinical study data:

On 15 February, 2019, Medtronic issued a statement regarding a programming error in the clinical data reporting isolated to the two and three year follow-up periods in our IN.PACT Global post-market study, part of the IN.PACT Admiral clinical programme for the treatment of femoropopliteal artery disease.

As we noted in our previous statement, this programming error impacted the IN.PACT paclitaxel safety analysis, which recently presented at the Leipzig Interventional Course [LINC; 22–25 January] in Leipzig, Germany and published online in the Journal of the American College of Cardiology (JACC).

The revised analysis has been accepted by JACC. Prior to publication of the revised manuscript, the authors of the study have issued a correction letter addressing key revisions to the data. The updated analysis will also be presented by Peter Schneider at the VIVA Physicians Vascular Leaders Forum (VLF) from March 1–2, 2019 in Washington, DC [USA].

It is important to reiterate that the initial conclusions from the patient level meta-analysis remain intact:

Data found no correlation between paclitaxel dose and long-term survival.
Data demonstrated no difference in mean nominal dose of paclitaxel between overall survival in patients treated with DCB and those who died.
At five years there was no statistically significant difference in all-cause mortality between the drug-coated balloon (DCB) and plain balloon angioplasty (PTA) arms.

In addition to the full cohort, a standard cohort has been included by the authors in the JACC analysis. This was done to correct a baseline imbalance between DCB and PTA by identifying a subgroup of DCB patients who met the inclusion criteria for the pivotal studies from the IN.PACT clinical programme, including IN.PACT SFA, IN.PACT Japan, and IN.PACT China. When only the subjects that mirror the baseline variables in the control PTA group are included, we observe a smaller difference in mortality. When adjusted for these baseline imbalances, all-cause mortality between DCB and PTA was 13.2% vs. 11% (p=0.188).

In line with our commitment to transparency, we have shared all our patient-level data with FDA in support of their paclitaxel safety analysis and will plan to do the same to support the upcoming independent VIVA Physicians analysis. Following publication of the revised JACC manuscript, we will also work to correct all impacted materials that live in the public domain.

Source Vascularnews

Duc Tin Clinic

Chia sẽ qua facebook bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua google bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua twitter bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua MySpace bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua LinkedIn bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua stumbleupon bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua icio bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua digg bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Chia sẽ qua yahoo bài: Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.